CCSD code L8621 – Ultrasound-guided foam sclerotherapy

Key takeaways

CCSD Code L8621 covers bilateral ultrasound-guided foam sclerotherapy performed in one session, distinct from L8620 (unilateral).

Most UK private insurers typically require pre-authorisation and medical necessity evidence for L8621, so confirm the criteria in each insurer’s provider portal.

The procedure note must confirm bilateral treatment, veins treated by name, sclerosant agent, volume per leg, real-time ultrasound guidance, and compression applied.

Pabau’s claims management software sends L8621 claims to Healthcode with the pre-authorisation reference attached to the invoice.

What CCSD Code L8621 covers

CCSD Code L8621 describes ultrasound-guided foam sclerotherapy for varicose veins performed bilaterally, meaning both legs are treated within the same clinical session. The code is defined in the official CCSD schedule. That is the coding system used by the major UK private health insurers, including Bupa, AXA Health, Vitality, Aviva and WPA. It is a private-sector-only code; the NHS does not use CCSD codes and has its own procedure classification (OPCS-4).

The code covers the complete bilateral treatment episode. That includes duplex ultrasound mapping within the session, foam preparation and injection under real-time ultrasound guidance, and compression applied afterwards. A diagnostic duplex scan performed on a different day is not bundled in, and it attracts its own CCSD code.

For how other Bupa-recognised venous codes are structured, see the Bupa CCSD code reference, which covers the wider procedural framework UK private insurers use. The neighbouring varicose vein codes sit in our CCSD code library.

The procedure: Ultrasound-guided foam sclerotherapy explained

Ultrasound-guided foam sclerotherapy (UGFS) treats varicose veins by injecting a foamed sclerosant into the affected vessel. The clinician watches the injection on continuous duplex ultrasound. The foam displaces blood within the vein and maximises contact between the agent and the vessel wall. The resulting endothelial injury makes the vein collapse and fibrose over the following weeks.

A bilateral session under CCSD Code L8621 proceeds in the following sequence:

1. Duplex mapping: Colour-flow duplex ultrasound identifies reflux on each leg. It checks the great saphenous vein (GSV), small saphenous vein (SSV), saphenofemoral junction (SFJ) and saphenopopliteal junction (SPJ). Segment diameters and reflux duration are recorded.
2. Foam preparation: The sclerosant is polidocanol or sodium tetradecyl sulphate, both licensed in the UK by the MHRA as liquid sclerosants. It is mixed with air or CO2 by the Tessari or double-syringe technique to produce a stable microfoam.
3. Injection under guidance: Needles or catheters are placed under real-time ultrasound into the target vessel on each leg. Foam is injected while the clinician monitors intravascular spread and avoids inadvertent deep venous or arterial injection.
4. Compression application: Class 2 compression stockings or bandaging is applied to both limbs immediately after injection and typically worn for one to two weeks.
5. Documentation: The procedure note records all elements listed in the documentation requirements section below before the patient leaves the treatment area.

NICE CG168 recommends endothermal ablation (endovenous laser or radiofrequency ablation) first for truncal reflux. It recommends UGFS where endothermal ablation is unsuitable. That order matters when you make the medical necessity case for an L8621 claim.

L8621 vs L8620: Which code applies?

The sole distinction between L8621 and L8620 is laterality within a single session. When both legs are treated in the same encounter, bill L8621. When one leg is treated, bill L8620. The rule is simple, yet the diagram below shows the one case that trips coders up: a second leg treated on a later date.

Where the second leg is treated at a follow-up visit on a separate date, each session is billed independently. The first visit uses L8620 (one leg treated); if only one leg is treated at the follow-up, that session also uses L8620. L8621 applies only when bilateral treatment is completed within the same encounter. Insurers audit laterality against the procedure note and the number of pre-auth sessions approved, so the session date and clinical record must align.

Related CCSD codes used alongside L8621

Vascular consultants treating bilateral varicose vein disease rarely bill L8621 in isolation. These related procedures often appear on the same claim or in the same treatment episode. Take each one’s code from the current CCSD schedule.

Insurers apply unbundling rules to CCSD claims. A duplex scan performed during the UGFS session to guide foam delivery is bundled into L8621. Do not bill it as a separate code on the same date. Check each insurer’s fee schedule guidelines, because the rules vary between Bupa, AXA Health, Vitality and WPA.

ICD-10 diagnosis codes that pair with L8621

UK private insurers require an ICD-10 diagnosis code on every CCSD claim. For varicose vein disease treated with UGFS, the appropriate codes fall within the I83 series. The WHO ICD-10 I83 codes carry no laterality, so the code must reflect the ulcer and inflammation status documented in the clinical note.

Clinical indications for bilateral UGFS

CCSD Code L8621 is appropriate when duplex ultrasound confirms bilateral truncal or tributary venous reflux and the patient meets the criteria for intervention. NICE CG168 sets the referral criteria and the treatment order, with endothermal ablation first and UGFS where that is unsuitable. The reflux threshold and the compression trial below come from typical insurer medical necessity criteria, not from NICE.

• Confirmed bilateral superficial venous reflux on duplex scan, with a duration exceeding 0.5 seconds at the SFJ or SSV/SPJ on each leg
• Symptoms attributable to reflux: Aching, heaviness, swelling, night cramps, or skin changes (lipodermatosclerosis, haemosiderin staining, eczema)
• CEAP classification C2 or above on each leg, with documentation of the C, E, A, and P findings
• Conservative management attempted (compression stockings for at least three months) and documented as having provided inadequate symptom relief
• Anatomy unsuitable for thermal ablation on one or both legs, or a recorded patient preference after a consent discussion covering laser and radiofrequency ablation

Insurers are entitled to request clinical records during an audit, and in England the CQC can inspect the same records. Keep the procedure note and referral documentation complete enough to satisfy both.

Pre-authorisation requirements

Most insurers typically require pre-authorisation before L8621 is performed. A claim without a valid authorisation reference is likely to be refused, however strong the clinical documentation. The table below lists evidence insurers commonly ask for. Requirements change, so confirm them in each insurer’s provider portal before treatment.

Always record the authorisation reference number in the patient file and include it on the invoice at the point of claim submission. A missing or misquoted authorisation number is one of the most avoidable reasons for an L8621 denial.

Documentation for a valid L8621 claim

An L8621 claim is only as strong as the procedure note supporting it. Insurers are entitled to request clinical records at any point during adjudication or a retrospective audit. A note that omits key procedural details can lead to a hold, a query or a denial.

The procedure note for CCSD Code L8621 must contain all of the following:

• Explicit confirmation that both legs were treated in the same session (the bilateral qualifier that differentiates L8621 from L8620)
• Names of the veins treated on each side. For example, right GSV from the SFJ to mid-thigh, and left SSV from the SPJ to mid-calf
• Sclerosant agent used and its licensed concentration (polidocanol or sodium tetradecyl sulphate)
• Volume of foam injected per leg, noted separately for each side
• Confirmation of real-time ultrasound guidance throughout the injection phase
• Post-procedure duplex assessment confirming intravascular foam position and absence of deep venous involvement
• Compression applied: Type (stocking or bandage), class, and limbs covered
• Clinician name, GMC number, and date of procedure

A structured digital procedure note can prompt clinicians through each of these fields. That cuts omissions and leaves an auditable record you can retrieve quickly when an insurer asks for it. UK GDPR also requires clinical records to be stored securely and kept for the appropriate retention period.

Cosmetic vs medical necessity: How insurers assess L8621

Most UK private health policies exclude cosmetic procedures, and varicose vein treatment sits in a contested grey area. Insurers accept that symptomatic varicose vein disease is a medical condition. They decline to cover purely aesthetic treatment, where the patient’s main reason for seeking it is appearance rather than symptoms.

For CCSD Code L8621 to clear the medical necessity threshold, the clinical record needs to demonstrate each of the following:

• CEAP classification: Documented C2 or higher on both sides, with the E (aetiology), A (anatomy), and P (pathophysiology) components recorded to support the C score
• Symptoms: Specific patient-reported symptoms linked to the affected limbs: Aching on prolonged standing, ankle oedema, venous cramps, skin changes. “Patient concerned about appearance” as the sole presenting complaint is insufficient.
• Duplex findings: Quantified reflux duration at the SFJ/SPJ and any tributary junctions, confirming haemodynamic significance
• Conservative management: A documented trial of class 2 compression stockings for at least three months. Where no trial took place, record the reason, such as a skin condition or limited mobility.
• Quality of life impact: A brief note of how symptoms affect daily life. Examples include being unable to stand through a working shift or to exercise regularly

Claims for patients with C2 disease and only mild symptoms are more likely to attract a query. When the treating consultant believes treatment is medically necessary, a covering letter helps. It should summarise the CEAP findings, the symptom burden and the failed conservative treatment, which lowers the risk of a cosmetic exclusion.

Common reasons L8621 claims are denied

Claims for CCSD Code L8621 are denied for a predictable set of reasons, and a documentation checklist catches most of them before submission.

• No pre-authorisation reference: A frequent and avoidable reason. The claim is submitted with a missing or incorrect auth number, and the insurer refuses it at adjudication without reviewing the clinical documentation.
• Wrong code submitted: L8620 billed instead of L8621 when both legs were treated in one session. This typically happens when the coding is done from an incomplete procedure note rather than the full record.
• Cosmetic exclusion applied: The insurer decides the presenting complaint was primarily aesthetic. The usual cause is thin CEAP documentation or a referral letter with no symptom narrative.
• Incomplete procedure note: Bilateral treatment not explicitly stated, veins not named, or ultrasound guidance not confirmed. The insurer’s clinical reviewer cannot verify the code is justified.
• Duplicate billing: L8620 and L8621 submitted for the same date of service, or L8621 submitted for two separate visits on different dates.
• No duplex report on file: The insurer requests supporting evidence during a post-payment audit and the practice cannot produce the scan report.

How to submit the claim, step by step

A correctly sequenced submission workflow prevents the most common L8621 denial causes before they arise.

1. Obtain pre-authorisation before booking the procedure. Contact the patient’s insurer with the proposed CCSD code (L8621), the treating consultant’s registration details, and the supporting clinical summary. Record the authorisation reference number and any session or fee limits specified.
2. Complete the procedure note on the day. Include all elements listed in the documentation requirements section above. Do not leave the note to be completed later from memory.
3. Select L8621 and any other procedure codes. Confirm that no same-day duplex scan code is being double-billed. Add a thermal ablation or phlebectomy code only if that procedure was also performed and pre-authorised.
4. Match the ICD-10 diagnosis code. Choose the I83 code that matches the documented ulcer and inflammation status. Use I83.0, I83.1 or I83.2 whenever the clinical note supports them.
5. Attach supporting documents. Include the duplex report, GP referral letter, and any covering letter from the consultant where cosmetic exclusion is a risk.
6. Submit via the insurer’s preferred channel. Most UK private insurers accept electronic claims through Healthcode or their own provider portals. Include the authorisation reference number in the designated field.
7. Track adjudication. Log the expected payment date and follow up on any queries within the insurer’s specified response window. Delayed responses to insurer queries are a secondary cause of write-offs on L8621 claims.

How Pabau keeps L8621 claims accurate

Many vascular practices still copy the CCSD code and the pre-authorisation number from emails into an invoice by hand. A wrong digit in either one sends a bilateral UGFS claim back as a query.

Pabau, the practice management platform we build, keeps the procedure note, the pre-authorisation reference and the invoice on one patient record. Its private practice claims software adds L8621 to the invoice and submits the claim to the insurer through Healthcode. You can then track the claim status through to payment.

Pabau’s features, including claims management and digital forms, support these workflows on every subscription. If you are still choosing a system, our roundup of UK medical billing software compares the main options.

Send CCSD claims to insurers without re-keying

Pabau keeps the L8621 code, pre-authorisation reference and procedure note on one patient record. Claims then go to UK private insurers through Healthcode.

Book a demo

Conclusion

Most L8621 problems start before the patient reaches the treatment room. Fix the session plan first. If both legs will be treated in one encounter, request authorisation for L8621. If treatment is staged, request L8620 for each visit.

The cosmetic exclusion is the risk worth planning around. A CEAP-graded note, a quantified duplex report and a documented symptom history give the insurer little reason to refuse.

Book a demo to see how Pabau links each UGFS note, pre-authorisation and Healthcode claim for your vascular practice.

Continue your research

Need a starting point for CCSD billing across Bupa-recognised procedures? Bupa CCSD codes and fee schedule covers the procedural code framework and fee structure used by Bupa for UK private practice invoicing.

Treating both legs without ultrasound guidance? CCSD code L8680 covers bilateral varicose vein injection sclerotherapy.

Planning thermal ablation on both legs instead? CCSD code L8541 explains billing for bilateral radiofrequency vein ablation.

Still choosing a billing system for private claims? Best medical billing software in the UK compares the options for practices billing UK insurers.

Frequently asked questions